U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H12O3
Molecular Weight 228.2433
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIOXSALEN

SMILES

CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1

InChI

InChIKey=FMHHVULEAZTJMA-UHFFFAOYSA-N
InChI=1S/C14H12O3/c1-7-4-12(15)17-14-9(3)13-10(6-11(7)14)5-8(2)16-13/h4-6H,1-3H3

HIDE SMILES / InChI

Molecular Formula C14H12O3
Molecular Weight 228.2433
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.drugs.com/cons/trioxsalen.html

Trioxsalen (trimethylpsoralen, trioxysalen or trisoralen) is a furanocoumarin and a psoralen derivative. It is obtained from several plants, mainly Psoralea corylifolia. Like other psoralens it causes photosensitization of the skin. It is administered either topically or orally in conjunction with UV-A (the least damaging form of ultraviolet light) for phototherapy treatment of vitiligo1 and hand eczema.2 After photoactivation it creates interstrand cross-links in DNA, which can cause programmed cell death unless repaired by cellular mechanisms. In research it can be conjugated to dyes for confocal microscopy and used to visualize sites of DNA damage.3 The compound is also being explored for development of antisense oligonucleotides that can be cross-linked specifically to a mutant mRNA sequence without affecting normal transcripts differing at even a single base pair.Trioxsalen was discontinued by the manufacturer in December 2002.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2311221
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TRISORALEN

Approved Use

Trioxsalen

Launch Date

1965
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
12.5 ng/mL
0.6 mg/kg single, oral
dose: 0.6 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIOXSALEN plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
31 μg/L
400 mg 1 times / day unknown, oral
dose: 400 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
TRIOXSALEN serum
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FED
3 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIOXSALEN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIOXSALEN serum
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
400 mg single, oral
Highest studied dose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Ki 0.1 uM]
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
RACK-1 acts with Rac GTPase signaling and UNC-115/abLIM in Caenorhabditis elegans axon pathfinding and cell migration.
2010-11-18
Analysis of active and inactive X chromosome architecture reveals the independent organization of 30 nm and large-scale chromatin structures.
2010-11-12
Conserved genes act as modifiers of invertebrate SMN loss of function defects.
2010-10-28
A developmental timing switch promotes axon outgrowth independent of known guidance receptors.
2010-08-05
Multivesicular body formation requires OSBP-related proteins and cholesterol.
2010-08-05
Structural determinants of photoreactivity of triplex forming oligonucleotides conjugated to psoralens.
2010-07-25
Rapid sampling of molecules via skin for diagnostic and forensic applications.
2010-07
Photoallergic contact dermatitis to 8-methoxypsoralen in Ficus carica.
2010-06
Whole-genome profiling of mutagenesis in Caenorhabditis elegans.
2010-06
Topical treatment in vitiligo and the potential uses of new drug delivery systems.
2010-05-07
Two very long chain fatty acid acyl-CoA synthetase genes, acs-20 and acs-22, have roles in the cuticle surface barrier in Caenorhabditis elegans.
2010-01-25
Trioxsalen derivatives with lipoxygenase inhibitory activity.
2009-12
The germinal center kinase GCK-1 is a negative regulator of MAP kinase activation and apoptosis in the C. elegans germline.
2009-10-14
Role of tacrolimus (FK506) 0.1% ointment WW in vitiligo in children and imperatives of combine therapy with Trioxsalen and Silymarin suspension in progressive vitiligo.
2009-10
Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden.
2009-05-05
Electron microscopy methods for studying in vivo DNA replication intermediates.
2009
Nematode homologue of PQBP1, a mental retardation causative gene, is involved in lipid metabolism.
2009
An unexpectedly high degree of specialization and a widespread involvement in sterol metabolism among the C. elegans putative aminophospholipid translocases.
2008-10-02
The HLH-6 transcription factor regulates C. elegans pharyngeal gland development and function.
2008-10
3-Methyladenine DNA glycosylase is important for cellular resistance to psoralen interstrand cross-links.
2008-08-02
DNA interstrand crosslinks repair in mammalian cells.
2008-06-07
Application of TILLING and EcoTILLING as Reverse Genetic Approaches to Elucidate the Function of Genes in Plants and Animals.
2008-06
BINOL-amino acid conjugates as triggerable carriers of DNA-targeted potent photocytotoxic agents.
2007-12-27
Counting mutagenized genomes and optimizing genetic screens in Caenorhabditis elegans.
2007-11-07
In vivo footprint of a picornavirus internal ribosome entry site reveals differences in accessibility to specific RNA structural elements.
2007-11
Food deprivation attenuates seizures through CaMKII and EAG K+ channels.
2007-09
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).
2007-06
Psoralen conjugates for visualization of genomic interstrand cross-links localized by laser photoactivation.
2007-03-22
Regulation of Caenorhabditis elegans body size and male tail development by the novel gene lon-8.
2007-03-20
Specific apoptosis induction in human papillomavirus-positive cervical carcinoma cells by photodynamic antisense regulation.
2007
Synthesis and biological in vitro evaluation of novel PEG-psoralen conjugates.
2006-12
TILLING is an effective reverse genetics technique for Caenorhabditis elegans.
2006-10-18
Permeability of psoralen derivatives in lipid membranes.
2006-10-01
Enhanced repair of DNA interstrand crosslinks in S phase.
2006-03-06
Properties of novel antisense oligonucleotides containing 2'-O-modified adenosine with a photo-reactive group.
2006
Occupational allergic contact dermatitis disseminated from multifunctional acrylates in ultraviolet-cured lacquers.
2006
Inhibition of interferon-gamma signaling by a mercurio-substituted dihydropsoralen in murine keratinocytes.
2005-12-05
Psoralen and coumarin photochemistry in HSA complexes and DMPC vesicles.
2005-09-10
Repair of DNA interstrand crosslinks may take place at the nuclear matrix.
2005-09-01
Psoralen photocrosslinking, a tool to study the chromatin structure of RNA polymerase I--transcribed ribosomal genes.
2005-08
Spectral study of interactions of 4,8,4'-trimethylpsoralen and 4,4'-dimethylangelicin dyes with DNA.
2005-07
Photoreaction of skin-sensitizing trimethyl psoralen with lipid membrane models.
2005-05-11
Disappearance of nucleosome positioning in mitotic chromatin in vivo.
2005-04-15
Interplay between human high mobility group protein 1 and replication protein A on psoralen-cross-linked DNA.
2005-03-22
5-(3-Phenylpropoxy)psoralen and 5-(4-phenylbutoxy)psoralen: mechanistic studies on phototoxicity.
2005-03
Synthesis and properties of photo-reactive antisense oligonucleotides containing 2'-O-psoralen-conjugated adenosine.
2005
Identification of ciliated sensory neuron-expressed genes in Caenorhabditis elegans using targeted pull-down of poly(A) tails.
2005
Comparison of oral psoralen-UV-A with a portable tanning unit at home vs hospital-administered bath psoralen-UV-A in patients with chronic hand eczema: an open-label randomized controlled trial of efficacy.
2004-12
Tandem mass spectrometry for the determination of the sites of DNA interstrand cross-link.
2004-11
Psoralen derivatives and longwave ultraviolet irradiation are active in vitro against human melanoma cell line.
2004-10-25
Patents

Sample Use Guides

In Vivo Use Guide
for vitiligo: Adults and children 12 years of age and over—20 to 40 milligrams (mg) taken two to four hours before ultraviolet light A (UVA) exposure. This treatment (trioxsalen and UVA) is given two or three times a week with the treatments spaced at least forty-eight hours apart.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:31:05 GMT 2025
Edited
by admin
on Mon Mar 31 18:31:05 GMT 2025
Record UNII
Y6UY8OV51T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRIOXYSALEN
INN   JAN   MART.   WHO-DD  
INN  
Preferred Name English
TRIOXSALEN
MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
TMP (PSORALEN)
Common Name English
Trioxysalen [WHO-DD]
Common Name English
4,5',8-TRIMETHYLPSORALEN
Common Name English
trioxysalen [INN]
Common Name English
TRIOXSALEN [USP IMPURITY]
Common Name English
TRIOXSALEN [USAN]
Common Name English
7H-FURO(3,2-G)(1)BENZOPYRAN-7-ONE, 2,5,9-TRIMETHYL-
Systematic Name English
TRIOXSALEN [MI]
Common Name English
2,5,9-Trimethyl-7H-furo[3,2-g][1]benzopyran-7-one
Systematic Name English
TRIOXYSALEN [MART.]
Common Name English
NSC-71047
Code English
TRISORALEN
Brand Name English
4,5',8-TRIMETHYLPSORALEN [IARC]
Common Name English
TRIOXSALEN [VANDF]
Common Name English
TRIOXSALEN [ORANGE BOOK]
Common Name English
TRIOXYSALEN [JAN]
Common Name English
TRIOXSALEN [USP-RS]
Common Name English
Classification Tree Code System Code
NDF-RT N0000007909
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
NDF-RT N0000175879
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
WHO-VATC QD05AD01
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
WHO-ATC D05AD01
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
WHO-ATC D05BA01
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
NDF-RT N0000007909
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
NCI_THESAURUS C29708
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
WHO-VATC QD05BA01
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
NDF-RT N0000007909
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID3023716
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
EVMPD
SUB11318MIG
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
SMS_ID
100000076929
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
DRUG CENTRAL
2759
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
RS_ITEM_NUM
1693009
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
MERCK INDEX
m11177
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY Merck Index
CAS
3902-71-4
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
ChEMBL
CHEMBL1475
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
ECHA (EC/EINECS)
223-459-0
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
RXCUI
10844
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY RxNorm
NCI_THESAURUS
C66640
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
NSC
71047
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
PUBCHEM
5585
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
INN
2064
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
DRUG BANK
DB04571
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
MESH
D014307
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
CHEBI
28329
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
WIKIPEDIA
TRIOXSALEN
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
FDA UNII
Y6UY8OV51T
Created by admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY